Familial Cancer

, Volume 16, Issue 3, pp 329–338 | Cite as

Novel and reported pathogenic variants in exon 11 of BRCA2 gene in a cohort of Sri Lankan young breast cancer patients

  • Sumadee De SilvaEmail author
  • Kamani Hemamala Tennekoon
  • Aravinda Dissanayake
  • Kanishka De Silva
  • Lakshika Jayasekara
Original Article


Women with breast carcinoma diagnosed before 40 years of age with a strong familial risk have a greater prevalence of germline BRCA1 or BRCA2 variants than late onset breast cancer. Previously germline variants in BRCA1 and BRCA2 genes were characterized in a cohort of Sri Lankan breast cancer patients unselected for age of onset. This study focused on young breast cancer patients who were screened for previously identified hotspot regions in BRCA2 gene. A total of 48 young breast cancer patients with family history of cancer and 25 healthy controls were studied. Direct sequencing was used to detect pathogenic and other sequence variants in the hotspot regions of BRCA2 gene. Thirty-six sequence variants including seven pathogenic (c.2411_2412delAA/p.Glu804Valfs*2, c.2500_2501insG/p.Leu834Cysfs*4, c.3881T>G/p.Leu1294*, c.4768A>T/p.Lys1590*, c.5645C>G/p.Ser1882*, c.5747delC/p.His1916Phefs*3, c.6728C>T/p.Ser2243Phe) and two likely pathogenic (c.1922C>T and c.3378A>T) variants, two intronic variants of unknown significance (c.1910-74T>C, c.1910-51G>T), two variants of uncertain significance (c.2324C>T c.5104C>T) and 23 benign variants were detected. Among them, seven were novel (pathogenic 5 and likely pathogenic 2). Prevalence of pathogenic and likely pathogenic variants in the hotspots regions of BRCA2 was 23 and 6.3 % respectively in this cohort. This justifies BRCA2 variant testing in young breast cancer patients with family history of cancer in Sri Lanka.


BRCA2 Hotspot regions Young breast cancer patients Sri Lanka 



The authors are very grateful to the Director and staff of the National Cancer Institute, Maharagama, Sri Lanka for their cooperation and all young patients who agreed to participate in this study, Dr. Vathsal Bandaranayake and Dr. Niroshan Atulugama for assistance with sample collection from breast cancer clinic.


This study was funded by National Science Foundation, Sri Lanka (Grant Number RG/2014/BT/04).

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.


  1. 1.
    Assi HA, Khoury KE, Dbouk H, Khalil LE, Mouhieddine TH, El Saghir NS (2013) Epidemiology and prognosis of breast cancer in young women. J Thorac Dis 5(Suppl 1):S2–S8. doi: 10.3978/j.issn.2072-1439.2013.05.24 PubMedPubMedCentralGoogle Scholar
  2. 2.
    Al-Ansari A, Al-Mawali K, Al-Bahrani B, Al-Moundhri MS (2013) BRCA1 gene molecular alterations in omani breast cancer patients. Gulf J Oncolog 1(14):45–51PubMedGoogle Scholar
  3. 3.
    Keegan THM, Press DJ, Tao L, DeRouen MC, Kurian AW, Clarke CA, Gomez SL (2013) Impact of breast cancer subtypes on 3-year survival among adolescent and young adult women. Breast Cancer Res 15(5):R95CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Armes JE, Egan AJM, Southey MC, Dite GS, McCredie MRE, Giles GG, Hopper JL, Venter DJ (1998) The histologic phenotypes of breast carcinoma occurring before Age 40 years in women with and without BRCA1 or BRCA2 germline mutations: a population-based study. Cancer 83(11):2335–2345CrossRefPubMedGoogle Scholar
  5. 5.
    Mavaddat N, Peock S, Frost D et al (2013) Cancer risks for BRCA1 and BRCA2 mutation carriers: results from prospective analysis of EMBRACE. J Natl Cancer Inst 105(11):812–822. doi: 10.1093/jnci/djt095 CrossRefPubMedGoogle Scholar
  6. 6.
    Narod SA (2014) Bilateral breast cancers. Nat Rev Clin Oncol 11(3):157–166. doi: 10.1038/nrclinonc.2014.3 CrossRefPubMedGoogle Scholar
  7. 7.
    Metcalfe K, Gershman S, Lynch HT, Ghadirian P, Tung N, Kim-Sing C, Olopade OI, Domchek S, McLennan J, Eisen A, Foulkes WD, Rosen B, Sun P, Narod SA (2011) Predictors of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers. Br J Cancer 104(9):1384–1392. doi: 10.1038/bjc.2011.120 CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Cancer Registry (2010) National Cancer Control Programme, Government Cancer Institute, Cancer Incidence Data, MaharagamaGoogle Scholar
  9. 9.
    Cancer Registry (2009) National Cancer Control Programme, Government Cancer Institute: Cancer Incidence Data, MaharagamaGoogle Scholar
  10. 10.
    Balmaña J, Díez O, Castiglione M, ESMO Guidelines Working Group (2009) BRCA in breast cancer: ESMO clinical recommendations. Ann Oncol 20(Suppl 4):19–20. doi: 10.1093/annonc/mdp116 PubMedGoogle Scholar
  11. 11.
    De Silva S, Tennekoon KH, Karunanayake EH, De Silva W, Amarasinghe I, Angunawala P (2011) Novel sequence variants and common recurrent polymorphisms of BRCA2 in Sri Lankan breast cancer patients and a family with BRCA1 mutations. Exp Ther Med 2 (6):1163–1170Google Scholar
  12. 12.
    De Silva W, Karunanayake EH, Tennekoon KH, Allen M, Amarasinghe I, Angunawala P, Ziard MH (2008) Novel sequence variants and a high frequency of recurrent polymorphisms in BRCA1 gene in Sri Lankan breast cancer patients and at risk individuals. BMC Cancer 8:214. doi: 10.1186/1471-2407-8-214 CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Kwong A, Shin VY, Ho JC, Kang E, Nakamura S, Teo SH, Lee AS, Sng JH, Ginsburg OM, Kurian AW, Weitzel JN, Siu MT, Law FB, Chan TL, Narod SA, Ford JM, Ma ES, Kim SW (2016) Comprehensive spectrum of BRCA1 and BRCA2 deleterious mutations in breast cancer in Asian countries. J Med Genet 53(1):15–23. doi: 10.1136/jmedgenet-2015-103132 CrossRefPubMedGoogle Scholar
  14. 14.
    Breast Cancer Information Core [BIC] (2016).
  15. 15.
    Miller SA, Dykes DD, Poleskey HF (1988) A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 16(3):12–15CrossRefGoogle Scholar
  16. 16.
    Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, Grody WW, Hegde M, Lyon E, Spector E, Voelkerding K, Rehm HL (2015) ACMG Laboratory Quality Assurance Committee. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med 17(5):405–424. doi: 10.1038/gim.2015.30 CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Rebbeck TR, Mitra N, Wan F, Sinilnikova OM, Healey S, McGuffog L, Mazoyer S, Chenevix-Trench G, Easton DF, Antoniou AC, Nathanson KL and the CIMBA Consortium (2015) Association of type and location of BRCA1 and BRCA2 mutations with risk of breast and ovarian cancer. JAMA 313(13):1347–1361. doi: 10.1001/jama.2014.5985 CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Hirotsu Y, Nakagomi H, Sakamoto I, Amemiya K, Mochizuki H, Omata M (2015) Detection of BRCA1 and BRCA2 germline mutations in Japanese population using next-generation sequencing. Mol Genet Genomic Med 3(2):121–129. doi: 10.1002/mgg3.120 CrossRefPubMedGoogle Scholar
  19. 19.
    Wong ES, Shekar S, Chan CH, Hong LZ, Poon SY, Silla T, Lin C, Kumar V, Davila S, Voorhoeve M, Thike AA, Ho GH, Yap YS, Tan PH, Tan MH, Ang P, Lee AS (2015) Predictive factors for BRCA1 and BRCA2 genetic testing in an Asian clinic-based population. PLoS ONE 10(7):e0134408. doi: 10.1371/journal.pone.0134408 CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Caputo S, Benboudjema L, Sinilnikova O, Rouleau E, Béroud C, Lidereau R; French BRCA GGC Consortium (2012) Description and analysis of genetic variants in French hereditary breast and ovarian cancer families recorded in the UMD-BRCA1/BRCA2 databases. Nucleic Acids Res 40(Database issue):D992–1002. doi: 10.1093/nar/gkr1160 CrossRefPubMedGoogle Scholar
  21. 21.
    Pohlreich P, Zikan M, Stribrna J, Kleibl Z, Janatova M, Kotlas J, Zidovska J, Novotny J, Petruzelka L, Szabo C, Matous B (2005) High proportion of recurrent germline mutations in the BRCA1 gene in breast and ovarian cancer patients from the Prague area. Breast Cancer Res 7(5):R728–R736CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Kim H, Cho DY, Choi DH, Choi SY, Shin I, Park W, Huh SJ, Han SH, Lee MH, Ahn SH, Son BH, Kim SW, Korean Breast Cancer Study Group, Haffty BG (2012) Characteristics and spectrum of BRCA1 and BRCA2 mutations in 3922 Korean patients with breast and ovarian cancer. Breast Cancer Res Treat 134(3):1315–1326. doi: 10.1007/s10549-012-2159-5 CrossRefPubMedGoogle Scholar
  23. 23.
    Toh GT, Kang P, Lee SS, Lee DS, Lee SY, Selamat S, Mohd Taib NA, Yoon SY, Yip CH, Teo SH (2008) BRCA1 and BRCA2 germline mutations in Malaysian women with early-onset breast cancer without a family history. PLoS ONE 3(4):e2024. doi: 10.1371/journal.pone.0002024 CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Cherbal F, Salhi N, Bakour R, Adane S, Boualga K, Maillet P (2012) BRCA1 and BRCA2 unclassified variants and missense polymorphisms in Algerian breast/ovarian cancer families. Dis Markers 32(6):343–353. doi: 10.3233/DMA-2012-0893 CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Science+Business Media Dordrecht 2016

Authors and Affiliations

  • Sumadee De Silva
    • 1
    Email author
  • Kamani Hemamala Tennekoon
    • 1
  • Aravinda Dissanayake
    • 2
    • 3
  • Kanishka De Silva
    • 2
  • Lakshika Jayasekara
    • 1
  1. 1.Institute of Biochemistry, Molecular Biology and BiotechnologyUniversity of ColomboColomboSri Lanka
  2. 2.National Cancer ResearchMaharagamaSri Lanka
  3. 3.Teaching Hospital JaffnaJaffnaSri Lanka

Personalised recommendations